赛诺医疗(688108) - 2024 Q3 - 季度财报

Revenue and Sales Performance - Revenue for the third quarter was RMB 104.79 million, a 25.76% increase year-over-year[3] - Year-to-date revenue reached RMB 318.49 million, up 30.20% compared to the same period last year[3] - The increase in revenue was primarily driven by a significant growth in sales of coronary products[7] - Total operating revenue for the first three quarters of 2024 reached 318,486,443.24 RMB, a significant increase from 244,617,074.10 RMB in the same period of 2023[16] - Sales revenue from goods and services reached 358,433,488.89 RMB, a notable increase from the previous year[20] Net Profit and Loss - Net loss attributable to shareholders for the third quarter was RMB -14.41 million[3] - Year-to-date net loss attributable to shareholders was RMB -6.74 million[3] - Net profit attributable to the parent company's shareholders was -241,473,911.19 RMB in Q3 2024, slightly worse than -234,729,458.31 RMB in 2023[15] - Net profit attributable to parent company shareholders was -6,744,452.88 RMB, a significant loss compared to the previous year[18] - Total comprehensive income was -6,900,442.91 RMB, indicating a substantial decline in overall financial performance[18] - Basic earnings per share were -0.02 RMB, indicating a loss per share[18] R&D Investment and Expenses - R&D investment for the third quarter was RMB 59.72 million, a 58.46% increase year-over-year[3] - Year-to-date R&D investment totaled RMB 151.95 million, up 28.67% compared to the same period last year[3] - R&D expenses increased to 106,407,498.18 RMB in the first three quarters of 2024, up from 80,498,702.34 RMB in 2023[16] Assets and Liabilities - Total assets as of the end of the reporting period were RMB 1.28 billion, a 7.95% increase from the end of the previous year[4] - Equity attributable to shareholders was RMB 857.51 million, a 4.58% increase from the end of the previous year[4] - Total assets as of Q3 2024 stood at 1,280,072,535.51 RMB, up from 1,185,821,379.98 RMB in the previous year[13][15] - Total liabilities for Q3 2024 were 381,222,588.88 RMB, compared to 324,171,588.85 RMB in 2023[14][15] - Long-term liabilities increased to 224,481,917.36 RMB in Q3 2024, compared to 172,899,093.28 RMB in 2023[14] - Development expenditure rose to 377,364,683.16 RMB in Q3 2024, up from 331,823,588.24 RMB in 2023[13] - Inventory levels slightly increased to 120,649,871.70 RMB in Q3 2024 from 118,220,173.59 RMB in the previous year[13] Cash Flow and Liquidity - Operating cash flow for the year-to-date period was RMB 49.72 million, a 37.18% increase year-over-year[3] - Cash flow from operating activities increased to 49,720,487.28 RMB, showing improved operational efficiency[20] - Cash flow from investing activities was -72,000,968.51 RMB, reflecting significant investment outflows[21] - Cash flow from financing activities was 59,422,575.01 RMB, indicating strong external funding support[21] - Total cash and cash equivalents at the end of the period were 224,939,661.92 RMB, showing a healthy liquidity position[21] - Total cash inflow from financing activities was 121,906,687.94 RMB, highlighting robust fundraising efforts[21] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 10,402[9] - Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd. holds 71,859,417 shares, representing 17.38% of total shares[9] - Guo Yanchao holds 22,770,854 shares, representing 5.51% of total shares[9] - China Bank - Guotai Jiangyuan Advantage Selection Flexible Allocation Mixed Securities Investment Fund holds 12,295,278 shares, representing 2.97% of total shares[9] - Tianjin Sunshine Guangye Enterprise Management Partnership holds 10,628,155 shares, representing 2.57% of total shares[9] - Huang Songlang holds 10,000,000 shares, representing 2.42% of total shares[9] - Tianjin Sunshine Deye Enterprise Management Partnership holds 8,208,381 shares, representing 1.99% of total shares[9] - Li Guangxin holds 7,852,056 shares, representing 1.90% of total shares[9] - China Bank - Guotai Zhiyuan Advantage Mixed Securities Investment Fund holds 7,642,073 shares, representing 1.85% of total shares[9] - China Construction Bank - Guotai Pharmaceutical Health Equity Securities Investment Fund holds 7,246,706 shares, representing 1.75% of total shares[10] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 amounted to 355,578,619.17 RMB, compared to 301,656,954.40 RMB in 2023[16] - Total assets impairment loss was -7,904,949.40 RMB, reflecting significant write-downs[18]